Osivax Influenza Vaccine Misses Primary Efficacy Goal
The flu vaccine candidate OVX836 failed to meet its target efficacy of 50 percent in a recent Phase 2b trial.
Updated on Oct. 15, 2026 in Diseases — General
Live Poll
Do you feel confident that new vaccine technologies will improve your protection against seasonal influenza?
Osivax reported that its influenza vaccine candidate, OVX836, reached a point estimate vaccine efficacy of 24% in a Phase 2b clinical trial. The study, which included 2,850 healthy adults, did not meet its primary target of 50% efficacy.
Why it matters
The findings support shifting the company strategy toward developing combination vaccines that incorporate OVX836 with traditional seasonal flu shots. This approach aims to provide a more comprehensive layer of protection against various influenza strains.
The Phase 2b trial observed efficacy point estimates of 28% for influenza-like illness and 24% for overall vaccine efficacy among 2,850 participants. The candidate vaccine, administered as a 480 microgram dose, targets the influenza A nucleoprotein antigen.
The players
Osivax
Osivax is a biotechnology company headquartered in Lyon, France, and Liège, Belgium, focused on developing universal influenza vaccines.
GC Biopharma
GC Biopharma is a South Korean pharmaceutical company that has entered into a collaboration agreement with Osivax to advance vaccine development.
The details
Researchers conducted the trial across Belgium, France, Finland, and Germany to evaluate the safety and immunogenicity of the vaccine. While failing to meet the primary goal, the vaccine maintained a safety profile that was consistent with findings from previous clinical studies.
Timeline
October 15, 2026: Osivax released the Phase 2b clinical trial results.
Q4 2027: Company plans to launch a new Phase 1/2 combination vaccine study.
The Big Picture
This trial follows a pattern set by the influenza A nucleoprotein antigen targeting research to move beyond strain-specific protection. The results shift the development focus toward combination platforms to enhance coverage against evolving flu viruses.
The results indicate that this specific vaccine candidate will not be available for public use as a standalone influenza treatment in the near term. Patients should continue relying on current seasonal influenza vaccines while combination options move through future clinical evaluation.
The takeaway
While the standalone vaccine fell short of its efficacy goal, the company is pivoting toward a combination approach to strengthen flu protection. Future research will determine if pairing novel antigens with standard vaccines provides a more effective clinical solution.
What happens next
Osivax is scheduled to initiate a Phase 1/2 clinical study for its combination vaccine candidate in the fourth quarter of 2027.
Further reading
For broader context on current vaccine research, visit the Diseases — General section.
More information
Review the full clinical trial study information on the official government registry.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you feel confident that new vaccine technologies will improve your protection against seasonal influenza?
